EGFR突变肺癌脑膜转移奥希替尼加量治疗1例  

EGFR mutation lung cancer with leptomeningeal metastasis treated with increased dosage of osimertinib:a case report

作　　者：赵隽[1] 韩宇 李全福[1] 金高娃[1] ZHAO Jun;HAN Yu;LI Quanfu;JIN Gaowa(Department of Oncology,Ordos Central Hospital,Ordos,Inner Mongolia,017000,China;Department of Respiratory,Ordos Central Hospital,Ordos,Inner Mongolia,017000,China)

机构地区：[1]鄂尔多斯市中心医院肿瘤内科,内蒙古鄂尔多斯017000 [2]鄂尔多斯市中心医院呼吸科,内蒙古鄂尔多斯017000

出　　处：《肿瘤药学》2021年第6期779-782,共4页Anti-Tumor Pharmacy

摘　　要：非小细胞肺癌(NSCLC)脑膜转移患者的生存期短,治疗方法有限。奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),可高效抑制EGFR敏感突变和EGFR T790M耐药突变,同时对EGFR突变的NSCLC软脑膜转移患者也有很好的疗效。本文报道1例奥希替尼加量至160 mg·d-1治疗EGFR突变肺腺癌脑膜转移,为临床治疗NSCLC难治性软脑膜转移提供参考。Non-small cell lung cancer(NSCLC)patients with leptomeningeal metastases(LM)have short survival and limited treatment.Osimertinib,the 3rd-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),can selectively and effectively inhibit both EGFR and T790M mutations.It also has shown promising activity in NSCLC patients with LM and EGFR mutation.Here we reported a case of successful treatment with an increase of osimertinib to 160 mg·d-1 for a NSCLC patient with LM and EGFR mutation,hoping to provide a reference for clinical NSCLC refractory LM.

关 键 词：奥希替尼 脑膜转移 非小细胞肺癌 EGFR突变 

分 类 号：R734.2[医药卫生—肿瘤] R739.45[医药卫生—临床医学]